Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Paul La Rosée, MD, Taiping Jia, BS, Shadmehr Demehri, Peter de Vries, PhD, Lynn Bonham, PhD, Junia V. Melo, MD, PhD, Jack W. Singer, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 1524.

https://doi.org/10.1182/blood.V106.11.1524.1524

Published: 2005

Journal Articles

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian J. Druker, Michael W. Deininger

Blood (2005) 106 (6): 2128–2137.

https://doi.org/10.1182/blood-2005-03-1036

Published: 2005

Journal Articles

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, Michael W. N. Deininger

Blood (2005) 106 (1): 227–234.

https://doi.org/10.1182/blood-2004-12-4771

Published: 2005

Includes: Supplemental data

Journal Articles

Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit.

Shadmehr Demehri, Amie S. Corbin, Marc Loriaux, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2004) 104 (11): 2426.

https://doi.org/10.1182/blood.V104.11.2426.2426

Published: 2004

Journal Articles

BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210 BCR-ABL in a Murine Model of CML.

Shadmehr Demehri, Thomas O’Hare, PhD, Lisa J. Wood, PhD, Marc Loriaux, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2004) 104 (11): 2564.

https://doi.org/10.1182/blood.V104.11.2564.2564

Published: 2004

Journal Articles

CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?.

Shadmehr Demehri, Thoralf Lange, MD, Peter Paschka, MD, Susan Branford, MD, Tamio Koizumi, MD, Takeshi Sugimoto, MD, Lay-Cheng Lim, MD, Beate Schultheis, MD, Thomas Kegel, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2004) 104 (11): 1018.

https://doi.org/10.1182/blood.V104.11.1018.1018

Published: 2004

Journal Articles

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Chester A. Metcalf, III, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David C. Dalgarno, John Iuliucci, Tomi K. Sawyer, Brian J. Druker, Michael W. Deininger

Blood (2004) 104 (11): 793.

https://doi.org/10.1182/blood.V104.11.793.793

Published: 2004

Journal Articles

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

Ian J. Griswold, Lei J. Shen, Paul La Rosée, Shadmehr Demehri, Michael C. Heinrich, Rita M. Braziel, Laura McGreevey, Andrea D. Haley, Neill Giese, Brian J. Druker, Michael W.N. Deininger

Blood (2004) 104 (9): 2912–2918.

https://doi.org/10.1182/blood-2003-05-1669

Published: 2004

NARROW

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit.

BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210 BCR-ABL in a Murine Model of CML.

CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?.

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only